Warning: The NCBI web site requires JavaScript to function. more...
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.
Serrao E, Odde S, Ramkumar K, Neamati N.
Retrovirology. 2009 Mar 5;6:25. Review. Erratum in: Retrovirology. 2009;6:33.
Related citations
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y.
Biochemistry. 2008 Sep 9;47(36):9345-54. Epub 2008 Aug 15.
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.
J Antimicrob Chemother. 2010 Jun;65(6):1262-9. Epub 2010 Apr 12.
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R.
Virology. 2010 Jul 5;402(2):338-46. Epub 2010 Apr 24.
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes.
Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, Xu H, Wainberg MA.
Retrovirology. 2009 Nov 11;6:103.
Integrase inhibitors: a novel class of antiretroviral agents.
Schafer JJ, Squires KE.
Ann Pharmacother. 2010 Jan;44(1):145-56. Epub 2009 Dec 29. Review.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).
J Antimicrob Chemother. 2008 Nov;62(5):914-20. Epub 2008 Aug 20.
Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.
Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ.
AIDS. 2008 Sep 12;22(14):1877-80.
Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1.
Evering TH, Markowitz M.
Drugs Today (Barc). 2007 Dec;43(12):865-77. Review.
Integrase inhibitors for the treatment of HIV infection.
Pace P, Rowley M.
Curr Opin Drug Discov Devel. 2008 Jul;11(4):471-9. Review.
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
Métifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D, Marchand C, Pommier Y.
AIDS. 2011 Jun 1;25(9):1175-8.
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Correll T, Klibanov OM.
Pharmacotherapy. 2008 Jan;28(1):90-101.
[Resistance to integrase inhibitors].
Garrido C, de Mendoza C, Soriano V.
Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:40-6. Review. Spanish.
Induced-fit docking approach provides insight into the binding mode and mechanism of action of HIV-1 integrase inhibitors.
Barreca ML, Iraci N, De Luca L, Chimirri A.
ChemMedChem. 2009 Sep;4(9):1446-56.
Raltegravir: the first HIV integrase inhibitor.
Cocohoba J, Dong BJ.
Clin Ther. 2008 Oct;30(10):1747-65. Review.
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.
Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA.
J Virol. 2010 Sep;84(18):9210-6. Epub 2010 Jul 7.
Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Buzón MJ, Marfil S, Puertas MC, Garcia E, Clotet B, Ruiz L, Blanco J, Martinez-Picado J, Cabrera C.
Antivir Ther. 2008;13(7):881-93.
Elvitegravir: a new HIV integrase inhibitor.
Shimura K, Kodama EN.
Antivir Chem Chemother. 2009 Oct 19;20(2):79-85. Review.
[Raltegravir: the first HIV integrase inhibitor. Introduction].
Gatell JM.
Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:1-2. Spanish. No abstract available.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on